Novartis AG Pre-Tax Profit Margin 2010-2023 | NVS

Current and historical pre-tax profit margin for Novartis AG (NVS) from 2010 to 2023. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue. Novartis AG pre-tax profit margin for the three months ending December 31, 2023 was .
Novartis AG Pre-Tax Profit Margin Historical Data
Date TTM Revenue TTM Pre-Tax Income Pre-Tax Margin
2023-12-31 $46.66B $9.12B 19.55%
2023-09-30 $46.02B $7.94B 17.26%
2023-06-30 $44.71B $7.98B 17.84%
2023-03-31 $43.86B $7.25B 16.53%
2022-12-31 $43.46B $7.18B 16.51%
2022-09-30 $50.20B $23.25B 46.31%
2022-06-30 $52.79B $24.89B 47.15%
2022-03-31 $53.00B $26.36B 49.73%
2021-12-31 $52.88B $26.14B 49.43%
2021-09-30 $56.14B $11.75B 20.92%
2021-06-30 $51.56B $10.93B 21.19%
2021-03-31 $49.88B $9.71B 19.46%
2020-12-31 $49.90B $9.88B 19.80%
2020-09-30 $45.83B $9.08B 19.81%
2020-06-30 $49.53B $9.08B 18.32%
2020-03-31 $49.93B $9.42B 18.87%
2019-12-31 $48.68B $8.94B 18.37%
2019-09-30 $47.86B $8.51B 17.79%
2019-06-30 $46.76B $8.36B 17.87%
2019-03-31 $46.39B $13.94B 30.06%
2018-12-31 $46.10B $14.21B 30.83%
2018-09-30 $47.37B $15.18B 32.05%
2018-06-30 $48.67B $15.37B 31.57%
2018-03-31 $49.51B $9.46B 19.11%
2017-12-31 $50.14B $9.00B 17.95%
2017-09-30 $49.58B $7.78B 15.68%
2017-06-30 $49.23B $7.61B 15.47%
2017-03-31 $49.41B $7.41B 15.00%
2016-12-31 $49.44B $7.82B 15.81%
2016-09-30 $49.63B $7.87B 15.86%
2016-06-30 $49.78B $7.77B 15.60%
2016-03-31 $50.00B $7.81B 15.62%
2015-12-31 $50.39B $8.13B 16.14%
2015-09-30 $50.94B $9.76B 19.16%
2015-06-30 $51.75B $11.12B 21.49%
2015-03-31 $52.81B $12.11B 22.94%
2014-12-31 $53.63B $12.27B 22.88%
2014-09-30 $52.60B $11.96B 22.74%
2014-06-30 $52.21B $10.92B 20.91%
2014-03-31 $51.54B $10.81B 20.96%
2013-12-31 $52.72B $10.81B 20.50%
2013-09-30 $49.87B $11.02B 22.10%
2013-06-30 $51.00B $11.32B 22.18%
2013-03-31 $52.26B $11.42B 21.84%
2012-12-31 $51.97B $11.24B 21.62%
2012-09-30 $57.49B $9.62B 16.73%
2012-06-30 $58.48B $9.75B 16.66%
2012-03-31 $59.07B $9.86B 16.69%
2011-12-31 $59.38B $10.56B 17.78%
2011-09-30 $58.84B $11.93B 20.28%
2011-06-30 $56.63B $11.82B 20.87%
2011-03-31 $53.43B $11.53B 21.58%
2010-12-31 $51.56B $11.70B 22.70%
2010-09-30 $50.24B $11.97B 23.83%
2010-06-30 $48.71B $11.67B 23.96%
2010-03-31 $47.53B $11.16B 23.47%
2009-12-31 $45.10B $9.92B 22.00%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $209.653B $45.440B
Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy, and xRNA. Novartis efforts to strengthen its wide and deep oncology portfolio by developing breakthrough treatments. Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio. In March 2015, Novartis acquired certain oncology products and pipeline compounds from Glaxo. In exchange, it sold its non-influenza Vaccines business to Glaxo. Also, the company has spun off the Alcon business into a separate company. In January 2015, Novartis divested its Animal Health division to Lilly. In July 2015, the company divested its influenza vaccines business to CSL Limited. Novartis has also acquired The Medicines Company, adding Leqvio, to its portfolio. Novartis sold its investment in Roche.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $731.812B 105.77
Novo Nordisk (NVO) Denmark $591.861B 45.48
Johnson & Johnson (JNJ) United States $372.169B 14.78
Merck (MRK) United States $332.279B 60.46
AbbVie (ABBV) United States $293.876B 15.18
AstraZeneca (AZN) United Kingdom $238.424B 20.73
Pfizer (PFE) United States $162.291B 20.17
Sanofi (SNY) $123.116B 11.62
Innoviva (INVA) United States $0.998B 7.01